bonyf NV / Key word(s): Corporate Action/Funds bonyf Announces Plans for Dual Listing on Nasdaq and Euronext Paris with a Five-Step Strategy 18-Feb-2025 / 12:24
Siegfried AG / Key word(s): Annual Results 18-Feb-2025 / 06:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is
Sartorius Stedim Biotech SA / Key word(s): Annual Results Sartorius Stedim Biotech releases Universal Registration Document 2024 17-Feb-2025 / 10:02 CET/CEST Aubagne, France | February
EQS-News: Formycon AG / Key word(s): Miscellaneous Formycon AG informs about recent developments in various biosimilar projects and invites to conference call 17.02.2025 / 09:27
Formycon AG / Key word(s): Study/Statement Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation
EQS-News: Volta Medical SAS / Key word(s): Study results Volta Medical Artificial Intelligence-Guided Cardiac Ablation Procedure Improves Treatment of Atrial Fibrillation 14.02.2025 / 11:30 CET/CEST
EQS-News: EBD Group / Key word(s): Conference BIO-Europe Spring® 2025 Propels the New Wave of Innovation in Milan 13.02.2025 / 16:30 CET/CEST The issuer is
EQS-News: Pentixapharm Holding AG / Key word(s): Conference First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU
EQS-News: Lindis Biotech GmbH / Key word(s): Regulatory Approval LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT
Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler Affected by Cyber Attack 13-Feb-2025 / 09:21 CET/CEST Disclosure of an inside information acc.